Why Poet Technologies Stock Crashed This Week
After more than doubling in the previous week's trading, Poet stock lost more than half of its value…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
1 signal unavailable — limited data for this stock
Trend
-11.8% vs SMA 50 · -29.7% vs SMA 200
Momentum
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $8.1B $8.0B–$8.1B | — | $12.97 | — | ±3% | High12 |
FY2026(current) | $7.9B $7.5B–$8.0B | ▼ -2.2% | $11.87 | ▼ -8.5% | ±11% | High11 |
FY2027 | $8.2B $7.8B–$8.4B | ▲ +3.6% | $12.78 | ▲ +7.7% | ±13% | High8 |
After more than doubling in the previous week's trading, Poet stock lost more than half of its value…

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end' pharmacovigilance service provider and this includes post marketing surveillance activities too.